Journal Article
. 2017 Aug;35(24).
doi: 10.1200/JCO.2016.70.3959.

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study

Anne Kuijer 1 Marieke Straver 1 Bianca den Dekker 1 Annelotte C M van Bommel 1 Sjoerd G Elias 1 Carolien H Smorenburg 1 Jelle Wesseling 1 Sabine C Linn 1 Emiel J Th Rutgers 1 Sabine Siesling 1 Thijs van Dalen 1 
Affiliations
  • PMID: 28813638
  •     13 citations

Abstract

Purpose Gene-expression profiles increasingly are used in addition to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions. The Dutch guideline suggests use of validated gene-expression profiles in patients with estrogen receptor (ER) -positive, early-stage breast cancer without overt lymph node metastases. We aimed to assess the impact of a 70-gene signature (70-GS) test on CT decisions in patients with ER-positive, early-stage breast cancer. Patients and Methods In a prospective, observational, multicenter study in patients younger than 70 years old who had undergone surgery for ER-positive, early-stage breast cancer, physicians were asked whether they intended to administer adjuvant CT before deployment of the 70-GS test and after the test result was available. Results Between October 1, 2013, and December 31, 2015, 660 patients, treated in 33 hospitals, were enrolled. Fifty-one percent of patients had pT1cN0, BRII, HER2-Neu-negative breast cancer. On the basis of conventional clinicopathological characteristics, physicians recommended CT in 270 (41%) of the 660 patients and recommended withholding CT in 107 (16%) of the 660 patients. For the remaining 43% of patients, the physicians were unsure and unable to give advice before 70-GS testing. In patients for whom CT was initially recommended or not recommended, 56% and 59%, respectively, were assigned to a low-risk profile by the 70-GS (κ, 0.02; 95% CI, -0.08 to 0.11). After disclosure of the 70-GS test result, the preliminary advice was changed in 51% of patients who received a recommendation before testing; the definitive CT recommendation of the physician was in line with the 70-GS result in 96% of patients. Conclusion In this prospective, multicenter study in a selection of patients with ER-positive, early-stage breast cancer, 70-GS use changed the physician-intended recommendation to administer CT in half of the patients.

A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy.
Pu Cheng, Zhen Wang, +3 authors, Jian Huang.
Oncotarget, 2017 Dec 22; 8(61). PMID: 29262565    Free PMC article.
Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.
Julia E C van Steenhoven, Anne Kuijer, +12 authors, Thijs van Dalen.
Genes (Basel), 2018 May 19; 9(5). PMID: 29772837    Free PMC article.
A prognostic 10-lncRNA expression signature for predicting the risk of tumour recurrence in breast cancer patients.
Jianing Tang, Jiangbo Ren, +6 authors, Gaosong Wu.
J Cell Mol Med, 2019 Aug 21; 23(10). PMID: 31429520    Free PMC article.
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Hatem Soliman, Varsha Shah, +11 authors, William Audeh.
BMC Cancer, 2020 Feb 02; 20(1). PMID: 32005181    Free PMC article.
MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature.
Deena M A Gendoo, Michael Zon, +5 authors, Benjamin Haibe-Kains.
Sci Rep, 2019 Jun 21; 9(1). PMID: 31217513    Free PMC article.
Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Kelsey H Natsuhara, Katya Losk, +7 authors, Rachel A Freedman.
Oncologist, 2018 Aug 05; 24(5). PMID: 30076279    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
Jianing Tang, Qiuxia Cui, +3 authors, Gaosong Wu.
J Cell Mol Med, 2019 May 28; 23(8). PMID: 31124293    Free PMC article.
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Front Oncol, 2020 Jun 02; 10. PMID: 32477946    Free PMC article.
Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
Julia E C van Steenhoven, Bianca M den Dekker, +6 authors, Thijs van Dalen.
Breast Cancer Res Treat, 2020 May 21; 182(1). PMID: 32430679    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
Stephane Thibodeau, Ioannis A Voutsadakis.
Eur J Breast Health, 2019 Jul 18; 15(3). PMID: 31312792    Free PMC article.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
R Wuerstlein, R Kates, +14 authors, WSG-PRIMe investigators in Germany, Austria, Switzerland.
Breast Cancer Res Treat, 2019 Feb 24; 175(2). PMID: 30796651    Free PMC article.